2021
Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors
Huo K, Notsuda H, Fang Z, Liu N, Gebregiworgis T, Li Q, Pham N, Li M, Liu N, Shepherd F, Marshall C, Ikura M, Moghal N, Tsao M. Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors. Journal Of Thoracic Oncology 2021, 17: 277-288. PMID: 34648945, DOI: 10.1016/j.jtho.2021.09.008.Peer-Reviewed Original ResearchConceptsEGFR tyrosine kinase inhibitorsTyrosine kinase inhibitorsLung cancerBRAF mutationsNon-small cell lung cancerNon-V600 BRAF mutationsPatient-derived xenograft modelsKinase inhibitorsCell lung cancerEGFR-TKI gefitinibSingle-agent vemurafenibV600E BRAF mutationRNA knockdownCell linesExpression of BRAFOff-target inhibitionCombination dabrafenibTKI gefitinibTargeted therapyLung adenocarcinomaXenograft modelEGFR kinase inhibitorsPatientsOncogenic driversBRAF
2016
Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1)*
Fang Z, Marshall C, Yin J, Mazhab-Jafari M, Gasmi-Seabrook G, Smith M, Nishikawa T, Xu Y, Neel B, Ikura M. Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1)*. Journal Of Biological Chemistry 2016, 291: 15641-15652. PMID: 27226556, PMCID: PMC4957048, DOI: 10.1074/jbc.m116.714196.Peer-Reviewed Original ResearchConceptsDisease-associated mutationsGTPase cycleIntrinsic GTP hydrolysis rateA57GRIT1 mutationsIntrinsic nucleotide exchange rateDisease-associated mutantsGTP hydrolysis rateNucleotide exchange rateReal-time NMRSmall guanosine triphosphataseHEK293T cellsPulldown assaysGuanosine triphosphataseGTP hydrolysisNoonan syndromeGTPase assaysDivergent residuesRIT1GTPase propertiesMutantsModest activationH-RASMutationsUrinary tract cancer